A “real world” analysis of records on over 11,000 patients around the world who suffer from atrial fibrillation finds that risk of hemorrhaging and stroke associated with Xarelto (rivaroxaban) was similar or lower than what was seen during clinical trials. In a report...

A “real world” analysis of records on over 11,000 patients around the world who suffer from atrial fibrillation finds that risk of hemorrhaging and stroke associated with Xarelto (rivaroxaban) was similar or lower than what was seen during clinical trials. In a report...

One of the big selling points for the anticoagulant Xarelto (rivaroxaban) was the claim that, unlike warfarin, patients didn't have to worry so much about food interactions and what they ate while taking the medication. With warfarin, patients must avoid a number of...

A recent clinical study intended to demonstrate the superiority of Xarelto (rivaroxaban) to aspirin in the prevention of secondary stroke has been abandoned by its sponsors, Bayer and Johnson & Johnson. The study, known as NAVIGATOR-ESUS, involved 7,000 participants,...

Once again, a jury has sided with corporate defendants Bayer and Johnson & Johnson's Janssen division in a lawsuit alleging injuries due to the use of their blood-thinning medication Xarelto. This most recent verdict comes in the wake of two trials in which the jury...

As the third lawsuit against Janssen Pharmaceuticals and Bayer AG gets underway, the Institute for Safe Medication Practices (ISMP) has released a disturbing report: the number of injuries and fatalities attributed to the anticoagulant medication Xarelto in 2016 was...

Bayer Healthcare and Janssen Pharmaceuticals, manufacturers of the anti-coagulant Xarelto (rivaroxaban), currently face more than 15,000 lawsuits, alleging that they were aware of the risk of dangerous and even fatal bleed-outs and failed to inform the public as well...

The most recent clinical study of Xarelto (rivaroxaban) has been halted more than a year early, because Bayer AG, the drug's original developer and sponsor of the trial, is satisfied with the results. That study, known as “Rivaroxaban for the Prevention of Major...

As of mid-December 2016, Janssen Pharmaceuticals is facing more than 15,000 lawsuits (most of which have been consolidated into multidistrict litigation in Louisiana with approximately 1,000 scheduled in Pennsylvania) over its “new generation” anti-coagulant...

Recently, the British Medical Journal (BMJ) published a report regarding a clinical trial that resulted in FDA approval of the anticoagulant medication Xarelto (rivaroxaban). It involved the use of a device known as the INRatio, a meter designed to monitor the levels...